No Detail Found!

Attenuation of PTZ Induced Generalized Clonic and Myoclonic Seizures by Meloxicam

Author(s)
Kalpana Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University Karachi, Pakistan
Sayyed Mudasar Hussain Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University Karachi, Pakistan
Uzair Nisar Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University Karachi, Pakistan
Md. Jamal Department of Pharmacy, City University of Science and Information Technology, Peshawar, Pakistan.
Shabana Usman Simjee H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
Abstract
Background: Millions of people worldwide suffer from epilepsy, a condition marked by repeated seizures, with about one-third of patients not being well controlled by the antiepileptic medications now on the market. In experimental settings, the Pentylenetetrazol (PTZ) model is frequently employed to cause seizures, offering a framework for assessing possible therapies. Since inflammation is a key factor in the epilepsy etiology, nonsteroidal anti-inflammatory medications (NSAIDs) with specific COX-2 inhibitors like meloxicam may have neuroprotective effects. Objective: To evaluate meloxicam's anticonvulsant qualities in a mouse model of PTZ-induced seizures is the main aim of this study. Materials & Methods: Five groups of male NAVAL MEDICAL RESEARCH INSTITUTE(NMRI) mice were established: control, diazepam + PTZ, meloxicam (25 mg/kg) + PTZ, meloxicam (15mg/kg) + PTZ, and PTZ only. Tukey and ANOVA's post-hoc test were used for the statistical analysis of the observed parameters for seizure onset, duration, severity, and post-seizure outcomes. Results: When compared to the PTZ-only group, meloxicam exhibited improved survival rates, decreased seizure length and severity, and markedly delayed the start of the first myoclonic jerk and generalized seizures. With a 90% survival rate, the high-dose meloxicam group (15 mg/kg) showed the most noticeable effects. Discussion: In the acute PTZ model, meloxicam significantly reduced the occurrence of generalized clonic and myoclonic seizures, indicating its potent anticonvulsant effects. This outcome is likely due to meloxicam's COX-2 inhibition and TgF beta inhibition, which reduces the neuroinflammation and stabilizes neuronal excitability. By lowering pro-inflammatory prostaglandins that contribute to seizure susceptibility, meloxicam not only modulates seizure activity but may also offer neuroprotective benefits. These findings suggest meloxicam's potential as a therapeutic option in epilepsy. Conclusion: Meloxicam has demonstrated potential as an anticonvulsant medication in PTZ-induced seizures, indicating the need for additional research into its long-term effectiveness and procedures of action in the epilepsy'streatment.
Publication Details
Page(s) 135-141
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 2, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Neuroprotection, Pentylenetetrazol (PTZ), Neuroinflammation, COX-2 inhibitor, Seizure model, Meloxicam, Epilepsy
References
Thijs RD,Surges R,O'Brien TJ,Sander JW . .Epilepsy in adults. Lancet. 2019 Feb, 30686584(18) : 32596-0.
Ghosh S,Sinha JK,Ghosh S,Sharma H,Bhaskar R,Narayanan KB . .A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. Brain Sci. 2023 Sep, 10(9) : PMC10527076.
Löscher W,Klein P. .2021 .The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs, 10(9) : PMC8408078-1034.
Vezzani A,French J,Bartfai T,Baram TZ .2010 .Epub 2010 Dec 7. 2011 Jan;7, 178(1) : PMC3378051-40.
Mukhtar I. .2020 .Inflammatory and immune mechanisms underlying epileptogenesis and epilepsy: From pathogenesis to treatment target. Seizure, 33011590 : 65-79.
Ghlichloo I,Gerriets V.,Nonsteroidal AntiInflammatory Drugs (NSAIDs) [ V.,Available V. . .Treasure Island (FL): StatPearls Publishing; 2024 Jan-. , : .
Auriel E,Regev K,Korczyn AD .2014 .Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. -7020- 4086-3, 24365321 : 00038-2.
Ju Z,Li M,Xu J,Howell DC,Li Z,Chen FE .2022 .Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years. Acta Pharm Sin B, 01(6) : PMC9214066-2807.
Sanz P,Rubio T,Garcia-Gimeno MA . .Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs. Int J Mol Sci. 2024 Apr, 10(8) : PMC11049926.
Resnick DK,Graham SH,Dixon CE,Marion DW .1998 .Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma, 9872457(12) : 1005-13.
Łukawski K,Czuczwar SJ . .Oxidative Stress and Neurodegeneration in Animal Models of Seizures and Epilepsy. 2023 May, 10(5) : PMC10215527.
Amin F,Tabassum S,Sarwar S,Qureshi R,Sohaib KM,Riaz N .2022 .Neuroprotective Effect of Otostegialimbata Against PTZInduced Mice Model of Epilepsy by Attenuated Expression of p-NFκB and TNF-α. Front Neurosci, 16 : .
Sahin B,Akkaya R,Karabulut S. Meloxicam .2022 .a selective COX-2 inhibitor, displays anticonvulsive effects in pentylenetetrazoleinduced acute seizures in mice through GABA and glutamate mediated mechanism. Exp Biomed Res, 5(1) : 48-57.
Ugidos IF,González-Rodríguez P,SantosGaldiano M,Font-Belmonte E,AnuncibaySoto B,Pérez-Rodríguez D .2023 .Neuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments. Neural Regen Res, 10(9) : PMC10233777-5374.
Vezzani A,Lang B,Aronica E.,Immunity E. . .. PMID: 26684336; PMCID: PMC4743070., 18(2) : .
Terrone G,Balosso S,Pauletti A,Ravizza T,Vezzani A .2019 .Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology. 2020 May, 31421074 : 107742.
Vezzani A,Fujinami RS,White HS,Preux PM,Blümcke I,Sander JW .2016 .Infections, inflammation and epilepsy. Acta Neuropathol, 10(2) : PMC4867498-234.
Löscher W,Howe CL .2022 .Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection. Front Mol Neurosci, 15 : .
Rawat C,Kukal S,Dahiya UR,Kukreti R . .Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. 2019 Oct, 10(1) : PMC6822425.
Riva A,Golda A,Balagura G,Amadori E,Vari MS,Piccolo G .2021 .New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment. 2021 Dec, 10 : PMC8690245.
Mendiola AS,Cardona AE . .The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna), 10(5) : PMC5699978-795.
Jurcau A,Simion A . .Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies. Int J Mol Sci. 2021 Dec, 10(1) : PMC8744548.
Henshall DC .2007 .Apoptosis signalling pathways in seizure-induced neuronal death and epilepsy. Biochem Soc Trans, 17371290 : 421-3.
Hakan T,Toklu HZ,Biber N,Ozevren H,Solakoglu S,Demirturk P .2010 .Epub 2009 Aug 5. Neurol Res, 19660237(6) : 629-35.
El-Malah AA,Gineinah MM,Deb PK,Khayyat AN,Bansal M,Venugopala KN . .Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. 2022 Jul, 10(7) : PMC9318302.
Zaitsev AV . .. Molecular and Cellular Mechanisms of Epilepsy 2.0. Int J Mol Sci. 2023 Dec, 10(24) : PMC10743424.
Rojas A,Jiang J,Ganesh T,Yang MS,Lelutiu N,Gueorguieva P . .Epub 2013 Nov 8. Epilepsia, 10(1) : PMC3956447-25.
0

Citations

0

Downloads

9

Views